MIS REPORT ON BEXIMCO PHARMA

1. Acknowledgement..........................................................................................................3 2. Financial Reports........................................................................................................4 3. MIS Report:..........................................................................................................10 4. Problems & Solutions......................................................................................13 5. Conclusion....................................................................................................14

1. Acknowledgement
Beximco Pharmaceuticals Ltd (BPL) is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs) in Bangladesh. The company is the largest exporter of pharmaceuticals in the country and its state-of-the-art manufacturing facilities are certified by global regulatory bodies of Australia, Gulf nations, Brazil, among others. The company is consistently building upon its portfolio and currently producing more than 400 products in different dosage forms covering broader therapeutic categories which include antibiotics, antihypertensives, antidiabetics, antireretrovirals, anti asthma inhalers etc, among many others. With decades of contract manufacturing experience with global MNCs, skilled manpower and proven formulation capabilities, the company has been building a visible and growing presence across the continents offering high quality generics at the most affordable cost. Ensuring access to quality medicines is the powerful aspiration that motivates more than 3000 employees of the organization, and each of them is guided by the same moral and social responsibilities the company values most.

2. Financial Reports
The financial statements (Balance sheet, Income Statement) of Beximco Company for the year 2007, 2008 and 2009 are presented below:

2.1 Balance Sheet 2007

BEXIMCO PHARMACEUTICALS LIMITED Balance Sheet For the year ended 31 December 2007 Amount in Taka
ASSETS Non-Current Assets Property, Plant and Equipment- Carrying Value Investment in Shares Current Assets Inventories Accounts Receivable Loans, Advances and Deposits Cash and Cash Equivalents TOTAL ASSETS SHAREHOLDERS' EQUITY AND LIABILITIES Shareholders' Equity Issued Share Capital Share Premium Excess of Issue Price over Face Value of GDRs Capital Reserve on Merger Tax-Holiday Reserve Retained Earnings Non-Current Liabilities Long Term Borrowing-Net off Current Maturity (Secured) Liability for Gratuity & WPPF Deferred Tax Liability Current Liabilities and Provisions Short Term Borrowings Long Term Borrowing-Current Maturity Creditors and Other Payables Accrued Expenses Dividend Payable Income Tax Payable TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 9,029,643,482 8,992,942,392 36,701,090 2,923,775,458 1,652,480,291 499,680,792

11,953,418,940

8,250,939,647 1,145,070,430 1,489,750,000 1,689,636,958 294,950,950 42,354,953 3,189,176,356 2,074,506,357 1,776,449,778 246,704,610 51,351,969 1,627,972,936 907,582,327 343,604,498 271,814,118 60,052,739 3,285,324

11,953,418,940

2.2 Income Statement 2007

BEXIMCO PHARMACEUTICALS LIMITED

Income Statement For the year ended 31 December 2007 Particulars SALES Local Sales Export Sales Net Sales Revenue COST OF GOODS SOLD COST OF PRODUCTION Finished Goods (Opening) Finished Goods available Finished Goods (Closing) Cost of Physician Sample Cost of goods sold GROSS PROFIT Operating Expenses Administrative Expenses Selling, Marketing and Distribution Expenses Profit from operations Other Income Finance Cost Profit Before Contribution to WPPF Contribution to Workers' Profit Participation/ Welfare Funds Profit Before Tax Income Tax Expense Current Tax Deferred Tax Income/(Expense) Profit After Tax Transferred to Statement of Changes in Equity Earnings Per Share (of Tk. 10 /- each) (Adjusted EPS of 2006) Number of shares used to compute EPS 1,937,293,517 398,102,771 2,335,396,288 331,438,214 2,003,958,074 36,448,099 1,967,509,975 (1,967,509,975) 1,629,514,837
(974,736,690)

Amount 2,007 3,474,272,775 122,752,037 3,597,024,812

145,544,701 829,191,989 974,736,690 19,625,795 (254,742,392) 419,661,550 (19,983,883) 399,677,667 (46,609,789) (57,661,278) 11,051,489 353,067,878 3.08 114,507,043

2.3 Balance Sheet of 2008

BEXIMCO PHARMACEUTICALS LIMITED BALANCE SHEET For the year ended 31 December 2008 Amount in Taka

ASSETS Non-Current Assets Property, Plant and Equipment- Carrying Value Investment in Shares Current Assets Inventories Accounts Receivable Loans, Advances and Deposits Cash and Cash Equivalents TOTAL ASSETS SHAREHOLDERS' EQUITY AND LIABILITIES Issued Share Capital Share Premium Excess of Issue Price over Face Value of GDRs Capital Reserve on Merger Tax-Holiday Reserve Retained Earnings Non-Current Liabilities Long Term Borrowing-Net off Current Maturity (Secured) Liability for Gratuity & WPPF Deferred Tax Liability Current Liabilities and Provisions Short Term Borrowings Long Term Borrowing-Current Maturity Creditors and Other Payables Accrued Expenses Dividend Payable Income Tax Payable TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

11,957,773,787
11,921,072,697 36,701,090 2,861,891,654 1,505,288,093 234,530,326 503,916,401 544,509,106 73,647,728 14,819,665,441 10,450,202,145 1,259,577,470 1,489,750,000 1,689,636,958 294,950,950 4,005,112,020 1,767,431,029 1,446,500,600 274,419,253 46,411,419 2,602,032,267 1,461,666,227 648,165,841 263,176,822 81,776,450 3,169,568 144,077,359 14,819,665,441

2.4 Income Statement of 2008

BEXIMCO PHARMACEUTICALS LIMITED Income Statement For the year ended 31 December 2008 Particulars SALES Amount in Taka 2,008 4,010,167,059

Local Sales Export Sales Net Sales Revenue COST OF GOODS SOLD COST OF PRODUCTION Finished Goods (Opening) Finished Goods available Finished Goods (Closing) Cost of Physician Sample Cost of goods sold GROSS PROFIT Operating Expenses Administrative Expenses Selling, Marketing and Distribution Expenses Profit from operations Other Income Finance Cost Profit Before Contribution to WPPF Contribution to Workers' Profit Participation/ Welfare Funds Profit Before Tax Income Tax Expense Current Tax Deferred Tax Income/(Expense) Profit After Tax Transferred to Statement of Changes in Equity Earnings Per Share (of Tk. 10 /- each) (Adjusted EPS of 2009) Number of shares used to compute EPS

3,839,563,510 170,603,549 4,010,167,059

2,069,313,627 331,438,214 2,400,751,841 (358,010,498) 2,002,871,181 2,002,871,181 2,007,295,878 (1,008,501,030) 153,464,243 855,036,787 998,794,848 686,510 249,654,298 749,827,060 (35,706,050) 714,121,010 (168,779,737) (173,720,430) 4,940,693 545,341,273 4.33 125,957,747

2.5 Balance Sheet of 2009

BEXIMCO PHARMACEUTICALS LIMITED BALANCE SHEET 2009 For the year ended 31 December 2009
ASSETS Non-Current Assets Property, Plant and Equipment- Carrying Value Investment in Shares Current Assets Inventories

Amount in Taka 12,975,195,529 12,966,587,178 2,881,826 6,916,737,893 1,722,953,284

Accounts Receivable Loans, Advances and Deposits Cash and Cash Equivalents TOTAL ASSETS SHAREHOLDERS' EQUITY AND LIABILITIES Issued Share Capital Share Premium Excess of Issue Price over Face Value of GDRs Capital Reserve on Merger Tax-Holiday Reserve Retained Earnings Non-Current Liabilities Long Term Borrowing-Net off Current Maturity (Secured) Liability for Gratuity & WPPF Deferred Tax Liability Current Liabilities and Provisions Short Term Borrowings Long Term Borrowing-Current Maturity Creditors and Other Payables Accrued Expenses Dividend Payable Income Tax Payable TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

694,111,730 699,204,450 1,058,433,574 19,891,933,422 10,885,706,614 1,511,492,960 1,489,750,000 1,689,636,958 294,950,950 4,282,514,032 6,684,775,166 1,924,933,065 307,425,614 352,416,487 2,321,451,642 1,451,326,354 308,820,056 409,898,122 79,094,905 1,727,724 70,584,481 19,891,933,422

2.6 Income Statement of 2009

BEXIMCO PHARMACEUTICALS LIMITED Income Statement For the year ended 31 December 2009
Particulars SALES Local Sales Export Sales Net Sales Revenue COST OF GOODS SOLD Amount in Taka

4,596,129,162 272,125,753 4,868,254,915 2,566,206,626

COST OF PRODUCTION Finished Goods (Opening) Finished Goods available Finished Goods (Closing) Cost of Physician Sample Cost of goods sold GROSS PROFIT Operating Expenses Administrative Expenses Selling, Marketing and Distribution Expenses Profit from operations Other Income Finance Cost Profit Before Contribution to WPPF Contribution to Workers' Profit Participation/ Welfare Funds Profit Before Tax Income Tax Expense Current Tax Deferred Tax Income/(Expense) Profit After Tax Transferred to Statement of Changes in Equity Earnings Per Share (of Tk. 10 /- each) (Adjusted EPS of 2009) Number of shares used to compute EPS

2,833,352,262 358,010,498 3,191,362,760 (554,393,259) 2,636,969,501 (70,762,875) 2,566,206,626 2,566,206,626 2,302,048,289 1,085,573,358 215,192,547 1,085,573,331 1,001,282,411 198,986,379 (289,427,992) 910,840,798 (43,373,371) 867,467,427 (242,727,120) (242,727,120) 624,740,307 4.13 151,149,296

3. MIS Report:
We have audited the Balance Sheet and Income Statement of the Beximco Pharmaceuticals Limited of 3 years and have formulated a report which shows various growth rates and ratio that is described through graphs and charts.

BEXIMCO PHARMA
MIS Report Particulars
Net Sales in Taka % of Sales Growth COG % of COG Growth

2007
3,597,024,812 1,967,509,975

2008
4,010,167,059 11.49% 2,002,871,181 1.80%

2009
4,868,254,915 21.40% 2,566,206,626 28.13%

Gross Profit in Taka % of Gross Profit Growth Gross Profit to Sales Net Profit in Taka % of Net Profit Growth Net Profit to Sales Fixed Asset Current Asset Current Liabilities Share owners equity Return on Equity Fixed Assets Turnover ( Times) Current Ratio Quick Ratio

1,629,514,837 45.30% 353,067,878 9.82%

9,029,643,482 2,923,775,458 1,627,972,936 8,250,939,647

2,007,295,878 23.18% 50.06% 545,341,273 54.46% 14%

11,921,072,697 1,505,288,093 2,602,032,267 10,450,202,145

2,302,048,289 14.68% 47.29% 624,740,307 14.56% 13% 12,975,195,529 6,916,737,893 2,321,451,642 10,885,706,614 6% 0.375 2.979 2.237

4.28% 0.40 1.80 0.78

5% 0.336 0.579 0.488

3.1 MIS Chart on growth

Particulars 2007 % of Sales Growth % of COG Growth % of Gross Profit Growth % of Net Profit Growth Net Profit to Sales Return on Equity 0.00% 0.00% 0.00% 0.00% 9.82% 4.28% 2008 11.49% 1.80% 23.18% 54.46% 14% 5% 2009 21.40% 28.13% 14.68% 14.56% 13% 6%

B e x im c o P h a r m a M IS R e p o r t
6 0 .0 0 % 5 0 .0 0 % 4 0 .0 0 % Value 3 0 .0 0 % 2 0 .0 0 % 1 0 .0 0 % 0 .0 0 % % o f S a le % o f C O G o f G ro s % o f N e tN e t P ro fi t R e tu r n o n s % s to G r o w th G ro w th P r o fi t G roPwrthfi t G r o w th a le s o S E q u i ty P a r tic u la r s 2007 2008 2009

3.2 MIS Report on Balance Sheet

Particulars Fixed Assets Turnover ( Times) Current Ratio Quick Ratio

2007
0.40 1.80 0.78

2008
0.336 0.579 0.488

2009
0.375 2.979 2.237

M IS R e p o r t o n B a la n c e S h e e t
3 .5 0 3 .0 0 2 .5 0 2 .0 0 Value 1 .5 0 1 .0 0 0 .5 0 0 .0 0 2007 2008 Year 2009

F ix e d A s s e t s T u r n o v e r ( C u r r e n t R a t io Q u ic k R a t io

4. Problems & Solutions

Beximco Pharmaceuticals Ltd (BPL) is a well established pharmaceuticals company. Their sales and profit is growing day by day. From its current financial reports we can see that the company is on right course. They are growing day by day at a good speed but there is still huge scope for improvement. We found some problems and barriers faced by the company and or may call it inefficiency of Beximco Pharma. Some problems and constraints we find about the company are: Weakness in world marketing

 Tariff and non tariff barriers Costly products Need to conduct research Should use upgrade technologies Pricing constraints due to government policies Rising costs sophistication of legislative requirements and growing technological

From our point of view we consider that taking following steps will mostly remove the problems of the company and will certainly make the company better and better. Beximco Pharmaceuticals Ltd (BPL) has to try to add new products of different therapeutic classes in its portfolio and these products are highly appreciated by the health professionals. They have intensified and consolidated their marketing efforts in other overseas markets, like Myanmar, Kenya, Yemen and Vietnam. To capitalize immense opportunities in these overseas markets, they are bringing in more new and exciting brands in these markets. These efforts are already bringing in desired results. Entering into new horizons and establishing new overseas markets will help the process of globalization and will make the company internationally famous. Technology carries the promise of tomorrow. The benefits of technology belong to all of us benefits that create new opportunities and open doors to a better life. For example, the new inhaler plant of BPL has been designed in a way to ensure highest-possible quality at every stage of manufacturing and quality control. BPL has a commitment to the society to supply world class Active Pharmaceutical Ingredients (APIs). Therefore, BPL is not only engaged in formulations but also in fine chemicals business with a view to supplying cost effective quality materials to other local companies as well as for captive consumption. As their product cost is high so they have to sell their at a high rate. So they have to reduce their cost if they want people of every class buy their products. Overall Beximco Pharma need to simultaneously cut costs, improve standards of quality, shorten product development times, and introduce innovative products that will increase customers value.

5. Conclusion

From the analysis it becomes very clear that Beximco Pharma holds quite a favourable position in the consumers mind. Beximco is very tactfully promoting its product in international market. It has done considerable amount of research to analyze the consumer profile of international market. At present, it is trying to attract the attention of the consumer of different level. The main problem of Beximco is the high cost of products and the promotion of their new products. Therefore, this company is trying its level best to change the perception of its customers and thus change the selling method. At present, it is facing hard competition from other branded sporting goods. They are trying to position itself in the mind of customers and to reduce the products price so that it can be available to every level of consumers. So far, its promotional and marketing campaign has paid of and it holds more than the way Beximco is trying to position and promote itself is very logical and we can see only success in the days to come as they are working for healthier tomorrow.